Equibles does not estimate personal net worth.
Get an email with a short summary when Allogene Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ALLO alertsGeoffrey Parker is recorded as CFO at Allogene Therapeutics, Inc. (ALLO) since October 16, 2023. Allogene Therapeutics, Inc. reported in an 8-K filed September 2, 2026 that Geoffrey Parker retired as Executive Vice President and Chief Financial Officer, effective November 6, 2026. Allogene Therapeutics, Inc. reported in an 8-K filed October 16, 2023 that Geoffrey Parker was appointed Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective October 16, 2023. Geoffrey Parker has spoken on 1 earnings call across 1 company, most recently for Allogene Therapeutics, Inc. on May 13, 2026. Allogene Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Allogene Therapeutics, Inc. includes Zachary Roberts, M.D., Ph.D. (CEO and Board Member), Tim Moore (CTO), Timothy Moore (CTO) and 4 others.
“On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.”
“The Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective October 16, 2023.”
“As we execute against our key clinical milestones in 2026, we remain focused on maintaining a strong financial position that supports continued progress across our portfolio.”
2023-10-16–present
2023-10-16–2026-11-06
Biotechnology · Healthcare
CFO
2023-10-16–present
